Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Integrative multi-omics and drug–response characterization of patient-derived prostate cancer primary cells

Fig. 2

Oncogenic alterations in PCMR. a Overlapped mutated genes for tumor (red) and BPH (blue) primary cells identified by WES. b Variant classification of tumor primary cells identified by WES. c Variant types of tumor primary cells identified by WES. d The variant number of per tumor primary cell sample identified by WES. e Top 10 mutation genes of tumor primary cells. The fraction indicated the proportion of patients with mutation in this gene. The bar height indicated total mutations in this gene. Red, conservative in-frame deletion; green, disruptive in-frame deletion; pink, stop codon gained; blue, missense variant; purple, other variants. f The genomic alteration frequency of top 10 mutation genes in 7161 patients. Dark green represents mutations, blue represents deletions, red represents amplifications, and gray represents multiple alterations. Data were obtained from the cBioPortal. NEPC, prostate neuroendocrine carcinoma; CRPC, castration-resistant prostate cancer; PA, prostate adenocarcinoma. g The survival curve of four PCa-related genes and the combination of them (h) with/without gene mutations in cBioPortal. P-values are calculated by Log-rank test. i cBioPortal OncoPrint evaluate the mutations attributes of PCRCs from previous 22 studies shown in Supplementary Fig. 3a

Back to article page